Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Buenos Aires - Delayed Quote ARS

Johnson & Johnson (JNJ.BA)

12,425.00
+175.00
+(1.43%)
As of 3:44:11 PM GMT-3. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
88,821,000
88,821,000
85,159,000
79,990,000
78,740,000
Cost of Revenue
27,471,000
27,471,000
26,553,000
24,596,000
23,402,000
Gross Profit
61,350,000
61,350,000
58,606,000
55,394,000
55,338,000
Operating Expense
39,201,000
39,201,000
35,197,000
34,381,000
34,395,000
Operating Income
22,149,000
22,149,000
23,409,000
21,013,000
20,943,000
Net Non Operating Interest Income Expense
577,000
577,000
489,000
214,000
-130,000
Other Income Expense
-6,045,000
-6,045,000
-8,802,000
-1,868,000
-1,635,000
Pretax Income
16,687,000
16,687,000
15,062,000
19,359,000
19,178,000
Tax Provision
2,621,000
2,621,000
1,736,000
2,989,000
1,377,000
Net Income Common Stockholders
14,066,000
14,066,000
35,153,000
17,941,000
20,878,000
Diluted NI Available to Com Stockholders
14,066,000
14,066,000
35,153,000
17,941,000
20,878,000
Basic EPS
1.17
1.17
2.78
1.37
1.59
Diluted EPS
1.16
1.16
2.74
1.35
1.56
Basic Average Shares
12,036,500
12,036,500
12,667,500
13,126,000
13,144,825
Diluted Average Shares
12,147,000
12,147,000
12,802,000
13,319,500
13,370,000
Total Expenses
66,672,000
66,672,000
61,750,000
58,977,000
57,797,000
Net Income from Continuing & Discontinued Operation
14,066,000
14,066,000
35,153,000
17,941,000
20,878,000
Normalized Income
20,088,746.45
20,088,746.45
21,290,457.04
17,265,068
18,830,152
Interest Income
1,332,000
1,332,000
1,261,000
490,000
53,000
Interest Expense
755,000
755,000
772,000
276,000
183,000
Net Interest Income
577,000
577,000
489,000
214,000
-130,000
EBIT
17,442,000
17,442,000
15,834,000
19,635,000
19,361,000
EBITDA
24,781,000
24,781,000
23,320,000
26,605,000
26,751,000
Reconciled Cost of Revenue
27,471,000
27,471,000
26,553,000
24,596,000
23,402,000
Reconciled Depreciation
7,339,000
7,339,000
7,486,000
6,970,000
7,390,000
Net Income from Continuing Operation Net Minority Interest
14,066,000
14,066,000
13,326,000
16,370,000
17,801,000
Total Unusual Items Excluding Goodwill
-7,145,000
-7,145,000
-9,002,000
-1,058,000
-1,109,000
Total Unusual Items
-7,145,000
-7,145,000
-9,002,000
-1,058,000
-1,109,000
Normalized EBITDA
31,926,000
31,926,000
32,322,000
27,663,000
27,860,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-1,122,253.55
-1,122,253.55
-1,037,542.96
-162,932
-79,848
12/31/2021 - 1/7/2008

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AZN.BA AstraZeneca PLC
41,825.00
+3.14%
 
GS71.F GSK plc
16.58
+2.66%
 
MRK.BA Merck & Co., Inc.
18,900.00
+1.34%
 
PFE.BA Pfizer Inc.
6,830.00
+3.17%
 
GLAXF GSK plc
18.46
+6.58%
 
LLY.MX Eli Lilly and Company
16,715.00
+3.82%
 
LLY0.DU Eli Lilly and Co
19.60
+2.08%
 
GRF.MC Grifols, S.A.
8.45
+0.64%
 
NOVN.SW Novartis AG
92.00
+1.21%
 
BAYN.DE Bayer Aktiengesellschaft
22.48
+1.70%